BriaCell Therapeutics (STU:8BT) Total Liabilities : €18.86 Mil (As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is BriaCell Therapeutics Total Liabilities?

BriaCell Therapeutics's Total Liabilities for the quarter that ended in Jan. 2024 was €18.86 Mil.

BriaCell Therapeutics's quarterly Total Liabilities declined from Jul. 2023 (€27.97 Mil) to Oct. 2023 (€15.25 Mil) but then increased from Oct. 2023 (€15.25 Mil) to Jan. 2024 (€18.86 Mil).

BriaCell Therapeutics's annual Total Liabilities increased from Jul. 2021 (€25.70 Mil) to Jul. 2022 (€31.70 Mil) but then declined from Jul. 2022 (€31.70 Mil) to Jul. 2023 (€27.97 Mil).

BriaCell Therapeutics Total Liabilities Historical Data

The historical data trend for BriaCell Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Total Liabilities Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Total Liabilities

Get a 7-Day Free Trial

1.01

3.58

25.70

31.70

27.97

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Total Liabilities	Get a 7-Day Free Trial															32.89	32.48	27.97	15.25	18.86

BriaCell Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BriaCell Therapeutics's Total Liabilities for the fiscal year that ended in Jul. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.628	+	(0	+	26.343
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	27.97

Total Liabilities	=	Total Assets (A: Jul. 2023 )	-	Total Equity (A: Jul. 2023 )
	=	24.556	-	-3.414
	=	27.97

BriaCell Therapeutics's Total Liabilities for the quarter that ended in Jan. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.602	+	(0	+	15.262
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	18.86

Total Liabilities	=	Total Assets (Q: Jan. 2024 )	-	Total Equity (Q: Jan. 2024 )
	=	11.228	-	-7.635
	=	18.86

BriaCell Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (STU:8BT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (STU:8BT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BCTX:USA BCT:Canada

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (STU:8BT) Headlines

No Headlines